This report was first published by Endpoints News. To see the original version, click here
A senior FDA official told reporters Thursday that the advisory committees the agency has used for years to gather outside perspective are “costly,” “slow” and use “pomp and flash instead of scientific truth.”
The FDA has previously raised some questions about adcomms during the Biden administration. But the new, harsh criticism comes during a time when some of the agency’s decisions have become more opaque, and companies have raised concerns about shifting agency standards. Staff reviewers’ judgments have sometimes been overruled from the top.
您已阅读22%（639字），剩余78%（2223字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。